Pembroke Reduces Workiva Stake in Recent SEC Filing Huawei Plans New Smartphone Chip This Fall Intensifying Competition With Nvidia and Apple Dow Jones Hits Record Close as AI Rally Falters SP 500 Nasdaq End Mixed UK Police Chiefs Call for Blocking Unsafe Social Media for Under16s Potential Regulatory Pressure on Tech Giants Michael Price Advocates Contrarian Approach to Navigate Market Volatility Fed Dissenters Explain No Votes Why They Opposed Rate Cut Signal TSM Q1 2026 Earnings EPS Surges Past Estimates Driven by AI Chip Demand SSTK Q4 2025 Earnings EPS Misses Estimates as Growth Headwinds Persist Sunstone Hotel Investors Inc SHO Q1 2026 Earnings Strong EPS Surprise of 98 Outperforms Estimates Despite Stock Dip Reynolds Consumer Products Q1 2026 Earnings EPS Surpasses Expectations by 136 Waste Connections Inc Q1 2026 Earnings EPS Beats Estimates Despite Flat Revenue Outlook AG Q1 2026 Earnings Silver Miner Misses EPS Estimates as Costs Weigh on Profitability Xos Inc XOS Holds Steady Near Support as Traders Await Catalyst WilliamsSonoma WSM Rises 242 as Retail Sector Momentum Drives Stock Above 200 Adamas Trust Inc ADAM Holds Steady Near Support in LowVolume Trading Nexalin Technology NXL Surges 16 Breakout Potential Above Resistance Pool Corporation POOL Shows Resilience with 16 Uptick Testing Key Resistance Trump Indicates Iran Nuclear Deal Largely Negotiated Strait of Hormuz Reopening Eyed Ultragenyx Q1 2026 Earnings WiderThanExpected Loss as No Revenue Reported Cantor Equity Partners III CAEP Holds Steady at 150 as Support and Resistance Levels Tighten UXIN Q1 2025 Earnings Loss Per Share Reported Amidst Market Challenges NXDR Q1 2026 Earnings Narrower Loss Per Share Boosts Sentiment DOMO Q1 2026 Earnings EPS Surprises with Profit Stock Jumps 465 Blackbaud Inc BLKB Q1 2026 Earnings Modest EPS Beat Points to Steady Execution in Cloud Transition INCR Q2 2023 Earnings EPS Surges Past Estimates as Profitability Strengthens IMMR Q3 2025 Earnings EPS Surges Past Estimates Stock Rises on Strong Licensing Performance Processa Pharmaceuticals Inc PCSA Q4 2025 Earnings WiderThanExpected Loss as Clinical Pipeline Progresses